8-K: C4 Therapeutics Reports Q2 2026 Results, Clinical Trials Advance

C4 Therapeutics announced second quarter 2026 financial results, highlighting progress in its cemsidomide clinical trials and a strong cash runway extending to the end of 2028.

Summary

• C4 Therapeutics reported financial results for the second quarter ended June 30, 2026.
• The company's Phase 2 MOMENTUM trial for cemsidomide in multiple myeloma is on track for enrollment completion in Q1 2027, with initial data expected in H2 2027.
• A Phase 1b trial combining cemsidomide with elranatamab is progressing, with updates expected in H2 2026 and data in mid-2027.
• An additional Phase 1b trial combining cemsidomide with other standard of care therapies is expected to initiate in H1 2027.
• Phase 1 data presented at EHA 2026 showed promising response rates (40% and 53% ORR at higher doses) and a favorable safety profile for cemsidomide.
• The company entered a new collaboration with Roche in April 2026, receiving a $20 million upfront payment.
• C4T raised approximately $33.5 million in net proceeds through its at-the-market program in Q2 2026.
• Total revenue for Q2 2026 was $6.6 million, a slight increase from $6.5 million in Q2 2025.
• Net loss for Q2 2026 was $23.6 million, an improvement from $26.0 million in Q2 2025.
• Cash, cash equivalents, and marketable securities stood at $300.4 million as of June 30, 2026, with an expected operational runway to the end of 2028.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, with strong clinical trial progress and a solid cash position, though revenue remains modest and net loss continues.

Positives

• Clinical trial progress for cemsidomide in multiple myeloma remains on track, with key data readouts anticipated in 2027.
• Phase 1 data presented at EHA 2026 demonstrated compelling anti-myeloma activity with 40% and 53% ORR at the two highest dose levels, and a differentiated safety profile with no cemsidomide-related discontinuations.
• A new collaboration with Roche was established in April 2026, including a $20 million upfront payment.
• The company successfully raised approximately $33.5 million in net proceeds through its ATM program.
• Cash, cash equivalents, and marketable securities increased to $300.4 million as of June 30, 2026.
• The company expects its current cash position to fund operations through the end of 2028.
• Net loss decreased to $23.6 million in Q2 2026 from $26.0 million in Q2 2025.
• Revenue saw a slight increase to $6.6 million in Q2 2026 from $6.5 million in Q2 2025, driven by the new Roche collaboration.

Negatives

• The company continues to incur significant net losses, with a loss of $23.6 million in Q2 2026.
• Revenue remains relatively low at $6.6 million for the quarter.
• The decrease in revenue from Merck collaborations offsets some of the gains from the new Roche agreement.
• Research and Development expenses, while slightly down, remain substantial at $24.5 million for the quarter.

Risks

• Uncertainties related to the initiation, timing, advancement, and conduct of preclinical and clinical studies.
• The risk that any one or more of the company's product candidates will cost more to develop or may not be successfully developed and commercialized.
• The risk that sufficient capital to fund future operations will not be available on acceptable terms or at the required times.
• The company's reliance on collaborations with other pharmaceutical companies.
• The potential for drug resistance in multiple myeloma patients.
• The competitive landscape in multiple myeloma treatment.

Future Outlook

The company expects its current cash, cash equivalents, and marketable securities to fund its operations through the end of 2028. Key clinical data readouts for cemsidomide trials are anticipated in 2027 and beyond. The company aims to deliver at least one development candidate to a collaboration partner by year-end 2026.

Management Comments

• "The first half of 2026 was a period of execution for cemsidomide, our next-generation IKZF1/3 degrader, and our clinical development plan."
• "As we enter the second half of the year, we remain focused on advancing the Phase 2 MOMENTUM trial, the Phase 1b combination trial with elranatamab and start-up activities for our additional Phase 1b combination trial with approved standard-of-care multiple myeloma therapies."
• "Together, these studies are expected to generate clinical milestones in 2027 and beyond and will support our vision of establishing cemsidomide as a potential backbone therapy for combination regimens in multiple myeloma."

Industry Context

StockSavvy.ai notes that C4 Therapeutics is operating in the highly competitive and innovative field of targeted protein degradation (TPD) for oncology. The company's focus on cemsidomide, a next-generation IKZF1/3 degrader, positions it within a key mechanism for multiple myeloma treatment. The collaboration with Roche highlights the industry's interest in novel modalities like degrader-antibody conjugates (DACs).

Comparison to Industry Standards

• The reported ORR of 40% and 53% in heavily pretreated relapsed refractory multiple myeloma patients at the highest doses of cemsidomide in Phase 1 trials is competitive, particularly given the favorable safety profile and lack of discontinuations. For context, approved therapies in similar patient populations often show variable response rates depending on prior treatments and combination regimens.
• The company's cash runway extending to the end of 2028 is a strong positive, providing ample time for clinical development, which is crucial in the biopharmaceutical industry where development cycles are long and capital intensive.
• The net loss of $23.6 million in Q2 2026 is typical for a clinical-stage biopharmaceutical company investing heavily in R&D. Industry peers often report similar or larger losses during the development phase.

Stakeholder Impact

• Shareholders: Positive impact from continued clinical development progress, strong cash position, and potential future value creation from cemsidomide and collaborations. Negative impact from ongoing net losses and the dilutive nature of ATM programs.
• Employees: Continued employment and potential for growth as the company advances its pipeline. Potential impact from stock-based compensation expenses.
• Collaborators (e.g., Roche): Potential for successful development of new therapies through the DAC modality, leading to future revenue streams and market opportunities.
• Patients: Potential for new and improved treatment options for multiple myeloma through the development of cemsidomide, especially in combination therapies.

Next Steps

• Complete enrollment in the Phase 2 MOMENTUM trial in Q1 2027.
• Provide initial investigator-assessed ORR data from the MOMENTUM trial in H2 2027.
• Provide an update on dose escalation progress from the Phase 1b trial with elranatamab in H2 2026.
• Deliver data from all cohorts of the Phase 1b trial with elranatamab in mid-2027.
• Initiate an additional Phase 1b trial combining cemsidomide with approved standard of care MM therapies in H1 2027.
• Present poster at the IMS Annual Meeting (September 23-26, 2026) on cemsidomide biomarker data.
• Deliver at least one development candidate to a collaboration partner by year-end 2026.
• Participate in the Cantor Global Healthcare Conference (September 9-11, 2026) and Wells Fargo Healthcare Conference (September 8-10, 2026).

Key Dates

Recommendation

The company shows promising clinical development and a strong cash position, but continues to operate at a loss. The positive clinical data and strategic collaborations are balanced by the inherent risks and long development timelines in the biopharmaceutical sector. A 'hold' recommendation reflects cautious optimism, awaiting further clinical data and potential commercialization.

Keywords

C4 Therapeutics, cemsidomide, multiple myeloma, targeted protein degradation, clinical trials, biopharmaceutical, drug development, hematology